Moderna Secures EU Tender for mRNA COVID-19 Vaccine Supply

Moderna has announced it won a tender to supply its mRNA COVID-19 vaccine in the European Union, Norway, and North Macedonia. The agreement allows 17 countries to access the vaccine for up to four years, providing opportunities to diversify their supply. The inclusion of pre-filled syringes aims to improve vaccination efficiency by reducing administration errors and saving time.

In September 2024, the European Commission approved a new version of Moderna's Spikevax, targeting the SARS-CoV-2 variant JN.1. This formulation is suitable for individuals aged six months and older. The deal highlights Moderna's commitment to enhancing vaccination campaigns and health security.